Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Neurogenic Overactive Bladder in Parkinson's Disease
NCT01421719Phase 4Completed
- Sponsor
- Stanford University
- Start
- Feb 2009
- Primary completion
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in Neurogenic Bladder (NB), sponsored by Stanford University. Primary endpoint: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. Started Feb 2009; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Neurogenic Bladder (NB)
Beyond the preview
Go deeper on NCT01421719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421719.